Loading the section
The price of Cytokinetics, Incorporated (CYTK) on October 9, 2026 is 62.81 USD, +1.29% on the day. Over 52 weeks the stock traded between 54.30 USD and 88.31 USD; the price now sits 23% of the way up that range. Over the past year the price changed by +3.06%. Market capitalization is 7.62 billion USD, rank 29 among 374 stocks of the same industry with a known capitalization.
Prices delayed by 15 minutes
Next earnings report: 04 November 2026 · Earnings calendar
Cytokinetics, Incorporated trades on Nasdaq under the ticker CYTK. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks CYTK has traded between 54.30 $ and 88.31 $. As of 09 October 2026 the price stood 22.67 % of the way from the 52-week low to the high.
Over one year CYTK shares rose 3.06 %; over six months they fell 3.99 %. Volatility over 90 days is 36.40 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 72.0, above the sector median of 3.9. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 60.31 | 62.79 | 59.79 | 62.01 | 3M |
| 07 October 2026 | 61.09 | 62.05 | 60.15 | 61.12 | 2M |
| 06 October 2026 | 62.20 | 62.53 | 60.68 | 61.35 | 3M |
| 05 October 2026 | 65.60 | 65.76 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Cytokinetics, Incorporated (CYTK) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2025-12-31, revenue was 88.0m $, net income was -785.0m $.
This summary is compiled automatically from SEC filings and exchange data.
Address:350 OYSTER POINT BOULEVARD ., SOUTH SAN FRANCISCO, CA, 94080, US
Cytokinetics, Incorporated reported revenue of 106M $ and a net loss of 830M $ over the last four quarters. Net margin is −784.02 %. Revenue changed by +450.60 % year over year. Earnings per share are −6.85 $. Market capitalisation is 7.6B $.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 62.19 |
| 62.70 |
| 3M |
| 02 October 2026 | 66.45 | 66.91 | 64.49 | 65.60 | 3M |
| 01 October 2026 | 65.73 | 67.27 | 65.30 | 65.62 | 2M |
| 30 September 2026 | 65.90 | 66.92 | 65.25 | 65.91 | 3M |
| 29 September 2026 | 65.91 | 66.52 | 64.38 | 65.64 | 2M |
| 28 September 2026 | 64.58 | 66.41 | 64.25 | 66.16 | 3M |
| 25 September 2026 | 65.66 | 65.95 | 64.44 | 64.66 | 2M |
| 24 September 2026 | 65.37 | 66.47 | 64.89 | 65.66 | 2M |
| 23 September 2026 | 67.02 | 67.39 | 64.73 | 65.81 | 2M |
| 22 September 2026 | 68.07 | 69.56 | 67.48 | 67.59 | 2M |
| 21 September 2026 | 69.30 | 69.50 | 67.35 | 67.56 | 2M |
| 18 September 2026 | 70.18 | 70.18 | 68.15 | 68.78 | 5M |
| 17 September 2026 | 70.64 | 71.05 | 68.92 | 69.92 | 1M |
| 16 September 2026 | 69.52 | 70.68 | 68.67 | 69.39 | 2M |
| 15 September 2026 | 72.13 | 72.19 | 68.55 | 69.31 | 3M |
| 14 September 2026 | 73.51 | 74.65 | 72.34 | 72.45 | 2M |
| 11 September 2026 | 74.66 | 75.98 | 73.50 | 73.77 | 2M |